MAPT and Alzheimer disease: This difference in the CSF Aβ1-42 cutoff can be expected because pathologic confirmation of AD requires the presence of both Aβ and tau pathologies and therefore implies more advanced disease stages that show lower average CSF Aβ1-42 levels.9